^
BIOMARKER:
NRAS Q61K
i
Other names: NRAS1, HRAS1, N-Ras Protein Part 4, Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog, NRAS, Neuroblastoma RAS Viral Oncogene Homolog, NRAS Proto-Oncogene, GTPase
Entrez ID:
Related biomarkers:
›
NRAS Q61K
|
Melanoma
|
NRAS Q61K
|
Melanoma
|
trametinib + dabrafenib Resistant: C3 – Early Trials
|
trametinib + dabrafenib Resistant: C3 – Early Trials
|
NRAS Q61K
|
HCC
|
NRAS Q61K
|
HCC
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
NRAS Q61K
|
Melanoma
|
NRAS Q61K
|
Melanoma
|
vemurafenib Resistant: C3 – Early Trials
|
vemurafenib Resistant: C3 – Early Trials
|
NRAS Q61K
|
Melanoma
|
NRAS Q61K
|
Melanoma
|
HL-085 Sensitive: C3 – Early Trials
|
HL-085 Sensitive: C3 – Early Trials
|
NRAS Q61K
|
Thyroid Gland Carcinoma
|
NRAS Q61K
|
Thyroid Gland Carcinoma
|
selumetinib Sensitive: C3 – Early Trials
|
selumetinib Sensitive: C3 – Early Trials
|
NRAS Q61K
|
NSCLC
|
NRAS Q61K
|
NSCLC
|
trametinib Sensitive: C3 – Early Trials
|
trametinib Sensitive: C3 – Early Trials
|
NRAS Q61K
|
Melanoma
|
NRAS Q61K
|
Melanoma
|
LY3009120 Sensitive: D – Preclinical
|
LY3009120 Sensitive: D – Preclinical
|
NRAS Q61K
|
Melanoma
|
NRAS Q61K
|
Melanoma
|
trametinib + palbociclib Resistant: D – Preclinical
|
trametinib + palbociclib Resistant: D – Preclinical
|
NRAS Q61K
|
Melanoma
|
NRAS Q61K
|
Melanoma
|
selumetinib Sensitive: D – Preclinical
|
selumetinib Sensitive: D – Preclinical
|
NRAS Q61K
|
Melanoma
|
NRAS Q61K
|
Melanoma
|
trametinib Resistant: D – Preclinical
|
trametinib Resistant: D – Preclinical
|
NRAS Q61K
|
Melanoma
|
NRAS Q61K
|
Melanoma
|
SBI-756 Sensitive: D – Preclinical
|
SBI-756 Sensitive: D – Preclinical
|
NRAS Q61K
|
Melanoma
|
NRAS Q61K
|
Melanoma
|
dabrafenib Resistant: D – Preclinical
|
dabrafenib Resistant: D – Preclinical
|
NRAS Q61K
|
Neuroblastoma
|
NRAS Q61K
|
Neuroblastoma
|
ASN007 Sensitive: D – Preclinical
|
ASN007 Sensitive: D – Preclinical
|
